Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/36—Opioid-abuse

Definitions

• the present invention refers to the use of derivatives of aryl (or heteroaryl) azolylcarbinols of general formula (I), and their physiologically acceptable salts, as medicinal products for human and/or animal therapeutics for the treatment of opioid addiction.
• Addiction especially from opioids like morphine can by all rights nowadays be called a mass disease.
• the present invention refers to the use of a carbinol compounds of general formula (II) wherein R 31 represents a hydrogen atom, a linear or branched alkyl radical, a linear or branched alkenyl radical, an optionally at least mono-substituted cycloaliphatic radical, which may contain at least one nitrogen atom as ring member, or a phenyl radical, R 32 represents a hydrogen atom, an optionally at least one nitrogen atom as ring member containing cycloaliphatic radical, which may be at least mono-substituted by a linear or branched alkyl radical and/or which may be bound via a linear or branched alkylene group, an NR 33 R 34- moiety, which is bound via a linear or branched alkylene group, or an NR 35 R 36 -moiety, which is bound via a linear or branched alkylene group, R 33 and R 34 , identical or different, represent hydrogen, a linear or branched
• “Drug Addiction treatment from addiction to opioids” is defined generally as the processes used to reduce (possibly up to zero) the amount of opioid the patient needs or is consuming.
• “Treatment of drug abuse of opioids” is defined as the medical therapeutic approaches to stop the abuse of this opioid or any opioid in general. This also includes detoxification and any replacement therapy of the opioid or similar approaches.
• “Treatment of dependency from opioids” is defined as the medical therapeutic approaches to lessen the dependency of a patient on this opioid or any opioid in general having the aim of reducing all dependency at all, whereas “dependency” is defined as being either psychologically or more prominently physiologically forced to consume the opioid.
• effects of a de-addiction treatment in the context of this invention is understood as including any side effect coming with any de-addiction treatment, especially any kind of withdrawal syndrome, whereas “ameliorating” or “amelioration” means bettering the conditions for the patient either objectively or subjectively, like less or less felt withdrawal syndromes.
• the addiction is not a disorder mediated by excess of substance P or it is preferred if the addiction is not a disorder connected to an excess of substance P.
• Opioids such as morphine, which belong to the class of centrally acting analgesics have a high risk of addiction.
• opioid includes substances having affinity for one or more of the opioid receptors such as the ⁇ -opioid receptors, the ⁇ -opioid receptors and/or the ⁇ -opioid receptors.
• Especially this invention refers to those opioids, which act as agonists or partial agonists on these receptors and who naturally also develop addiction.
• opioids which act as agonists or partial agonists on these receptors and who naturally also develop addiction. Examples include heroine and morphine and their analogues but also other opioids.
• alkyl and cycloalkyl radicals are understood as meaning saturated and unsaturated (but not aromatic), branched, unbranched and cyclic hydrocarbons, which can be unsubstituted or mono- or polysubstituted.
• C 1-2 -alkyl represents C1- or C2-alkyl
• C 1-3 -alkyl represents C1-, C2-or C3-alkyl
• C 1-4 -alkyl represents C1-, C2-, C3- or C4-alkyl
• C 1-5 -alkyl represents C1-, C2-, C3-, C4-, or C5-alkyl
• C 1-6 -alkyl represents C1-, C2-, C3-, C4-, C5- or C6-alkyl
• C 1-7 -alkyl represents C1-, C2-, C3-, C4-, C5-, C6- or C7-alkyl
• C 1-8 -alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7- or C8-alkyl
• C 1-10 -alkyl represents C1-, C2-, C3-, C4-, C5-, C
• C 3- 5 -cycloalkyl represents C3-, C4- or C5-cycloalkyl
• C 3-6 -cycloalkyl represents C3-, C4-, C5- or C6-cycloalkyl
• C 3-7 -cycloalkyl represents C3-, C4-, C5-, C6- or C7-cycloalkyl
• C 3-8 -cycloalkyl represents C3-, C4-, C5-, C6-, C7- or C8-cycloalkyl
• C 4-5 -cycloalkyl represents C4- or C5-cycloalkyl
• C 4-6 -cycloalkyl represents C4-, C5- or C6-cycloalkyl
• C 4-7 -cycloalkyl represents C4-, C5-, C6- or C7-cycloalkyl
• C 5-6 -cycloalkyl represents C5- or C6-cycloalkyl and C 5-7
• cycloalkyl in respect of cycloalkyl, the term also includes saturated cycloalkyls in which one or 2 carbon atoms are replaced by a heteroatom, S, N or O.
• mono- or polyunsaturated, preferably monounsaturated, cycloalkyls without a heteroatom in the ring also in particular fall under the term cycloalkyl as long as the cycloalkyl is not an aromatic system.
• alkyl and cycloalkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propinyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantyl, (if substituted also CHF 2 , CF 3 or CH 2 OH) as well as pyrazolinone, oxopyrazolinone, [1,4]
• substituted in the context of this invention is understood as meaning replacement of at least one hydrogen radical by F, Cl, Br, I, NH 2 , SH or OH
• Particularly preferred substituents here are F, Cl and OH.
• the hydrogen radical can also be replaced by OC 1-3 -alkyl or C 1-3 -alkyl (in each case mono- or polysubstituted or unsubstituted), in particular methyl, ethyl, n-propyl, i-propyl, CF 3 , methoxy or ethoxy.
• (CH 2 ) 3-6 is to be understood as meaning -CH 2 -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2- CH 2 -, -CH 2 -CH 2 -CH 2 -CH 2 - and -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -, (CH 2 ) 1-4 is to be understood as meaning -CH 2 -, -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2 - and -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -, (CH 2 ) 4-5 is to be understood as meaning -CH 2 -CH 2 -CH 2 -CH 2 - and -CH 2 -CH 2 -CH 2- CH 2 -CH 2 -, etc.
• aryl radical is understood as meaning ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, in particular 9H-fluorenyl or anthracenyl radicals, which can be unsubstituted or monosubstituted or polysubstituted.
• a heteroaryl radical is understood as meaning heterocyclic ring systems which have at least one unsaturated ring and can contain one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur and can also be mono- or polysubstituted.
• heteroaryls are furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole and quinazoline.
• substituted is understood as meaning substitution of the aryl or heteroaryl by R, OR, a halogen, preferably F and/or Cl, a CF 3 , a CN, an NO 2 , an NRR, a C 1-6 -alkyl (saturated), a C 1-6- alkoxy, a C 3-8- cycloalkoxy, a C 3-8 -cycloalkyl or a C 2-6 -alkylene.
• salt is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution.
• a counter-ion a cation or anion
• complexes of the active compound with other molecules and ions in particular complexes which are complexed via ionic interactions.
• physiologically acceptable salt means in the context of this invention any salt that is physiologically tolerated (most of the time meaning not being toxic-especially not caused by the counter-ion) if used appropriately for a treatment especially if used on or applied to humans and/or mammals.
• physiologically acceptable salts can be formed with cations or bases and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually a (deprotonated) acid - as an anion with at least one, preferably inorganic, cation which is physiologically tolerated - especially if used on humans and/or mammals.
• the salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH4, but in particular (mono)- or (di)sodium, (mono)- or (di)potassium, magnesium or calcium salts.
• physiologically acceptable salts can also be formed with anions or acids in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually protonated, for example on the nitrogen - as the cation with at least one anion which are physiologically tolerated - especially if used on humans and/or mammals.
• the salt formed with a physiologically tolerated acid that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or mammals.
• physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.
• solvate is to be understood as meaning any form of the active compound according to the invention in which this compound has attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates and alcoholates, e.g. methanolate.
• a polar solvent especially including hydrates and alcoholates, e.g. methanolate.
• the compounds of general formula (II) (as well as I, Ia, Ib and Ic) can be synthesised according to the procedures described in patents EP 289380, US 5,017,596 or WO 99/52525.
• the compounds of general formula (II) (as well as I, la, Ib and Ic) have a stereogenic centre and the invention refers both to the use of a pure enantiomer and to the use of a mixture of enantiomers.
• the enantiomers can be prepared by any of the procedures described in our patents WO 97/20817 (US 5,849,931), WO 99/02500 (US 6,187,930), WO 99/07684 (US 6,118,009) and WO 99/52525 (US 6,410,582).
• R 31 represents a hydrogen atom, a linear or branched C 1-4 alkyl radical, a linear or branched C 2-4 alkenyl radical, a 5- or 6-membered cycloaliphatic radical, which may contain at least one nitrogen atom as ring member and/or which may be at least mono-substituted by a linear or branched C 1-4 alkyl radical, or a phenyl radical, preferably a hydrogen atom, a linear or branched C 1-4 alkyl radical, a vinyl group, a cyclohexyl radical, an N-Methyl-piperidyl radical or a phenyl radical.
• R 32 represents a hydrogen atom, an optionally at least one nitrogen atom as ring member containing, 5- or 6-membered cycloaliphatic radical, which may be at least mono-substituted by a linear or branched C 1-4 -alkyl radical and/or which may be bound via a linear or branched C 1-4 -alkylene group, a NR 33 R 34- moiety, which is bound via a linear or branched C 1-4 alkylene group, or a NR 35 R 36- moiety, which is bound via a linear or branched C 1-4 alkylene group, preferably a hydrogen atom, an optionally at least one nitrogen atom as ring member containing, 5- or 6-membered cycloaliphatic radical, which may be at least mono-substituted by a linear or branched C 1-4 -alkyl radical and/or which may be bound via a linear or branched
• the compound according to formula II used is characterized in that R 33 and R 34 , identical or different, independently from one another represent hydrogen; a linear or branched C 1-4 alkyl radical or an unsubstituted benzyl radical, preferably hydrogen or a linear or branched C 1-4 alkyl radical.
• the compound according to formula II used is characterized in that R 35 and R 36 together with the bridging nitrogen atom represent a saturated, unsubstituted, optionally at least one oxygen atom as ring member containing, 5- or 6-membered heterocyclic radical.
• the compound according to formula II used is characterized in that X represents an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted thienyl radical, wherein in each case the substituents may be independently selected from the group consisting of a linear or branched C 1-4 alkyl radical, a linear or branched C 1-4 alkoxy radical, a linear or branched C 1-4 alkyl radical, which is at least partially fluorinated, a fluorine atom, a chlorine atom and a bromine atom, preferably represents an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted thienyl radical, wherein in each case the substituents may be independently selected from the group consisting of a methyl radical, a methoxy radical, a trifluoromethyl radical, a fluorine atom, a chlorine atom and a bromine
• At least one compound used according to the invention is a carbinol compound of general formula II is present, wherein R 31 represents a hydrogen atom, a methyl radical, an ethyl radical, an n-propyl radical, an iso-propyl radical, a sec-butyl radical, a tert-butyl radical, an n-butyl radical, a vinyl radical, a cyclohexyl radical, an N-methyl-piperidinyl group, or a phenyl group, R 32 represents a hydrogen atom, a monomethylaminoethyl group, a dimethylaminoethyl group, an aminoethyl group, a pyrrolidinylethyl group, a piperidinylethyl group, a methyl-benzyl-aminoethyl group, a morpholinylethyl group, a diisopropylaminoethyl group
• At least one compound according to formula II used is selected from the group consisting of
• the compound used (for the manifacture of a medicament for the treatment of neuropathic pain) is of the general formula (I) in which Ar represents a phenyl radical or a thienyl radical, with no substitutions or optionally with 1, 2 or 3 equal or different substituents, selected from a group consisting of fluoride, chloride, bromide, methyl, trifluoromethyl and methoxy;
• R 1 represents hydrogen or a lower alkyl group from C 1 to C 4 ;
• R 2 represents a dialkyl(C 1 -C 4 )aminoalkyl (C 2 -C 3 ), a monoalkyl(C 1 -C 4 )aminoalkyl (C 2 -C 3 ), an aminoalkyl (C 2 -C 3 ), or azaheterocyclylalkyl (C 2 -C 3 ) radical;
• Het represents a five-armed nitrogenated aromatic heterocycle that contains one to three nitrogen atoms
• the compound according to formula I used is characterized in that R 1 is selected from hydrogen or from a group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec -butyl and tert -butyl.
• the compound according to formula I used is characterized in that R 2 is selected from among a group consisting of dimethylaminoethyl, dimethylaminopropyl, diethylaminoethyl, diethylaminopropyl, methylaminoethyl, methylaminopropyl, aminoethyl, aminopropyl, piperidinylethyl, piperidinylpropyl, morpholinylpropyl, morpholinylethyl, pirrolidinylpropyl and pirrolidinylethyl; preferably dimethylaminoethyl, dimethylaminopropyl, diethylaminoethyl, piperidinylethyl, morpholinylpropyl, and pirrolidinylethyl.
• R 2 is selected from among a group consisting of dimethylaminoethyl, dimethylaminopropyl, diethylaminoe
• the compound according to formula I used is a compound of general formula (Ia) in which n is 1 or 2; R 3 is selected from: R 4 is selected from hydrogen, fluoride, chloride, bromide and methyl; R 5 and R 6 are independently selected from hydrogen, lower C (1-4) -Alkyl or together with the Nitrogen form an azaheterocyclic ring; R 7 is selected from the group consisting of hydrogen, fluoride, chloride, bromide, methyl, trifluoromethyl and methoxy; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate.
• R 3 is selected from: R 4 is selected from hydrogen, fluoride, chloride, bromide and methyl; R 5 and R 6 are independently selected from hydrogen, lower C (1-4) -Alkyl or together with the Nitrogen form an azaheterocyclic ring; R 7 is selected from the group consisting of hydrogen
• the compound according to formula Ia used is characterized in that R 7 is hydrogen.
• the compound according to formula la used is characterized in that R 4 is Methyl.
• the compound according to formula la used is characterized in that R 5 and R 6 are either hydrogen, CH 3 or C 2 H 5 or together with the Nitrogen form a piperidinyl, morpholinyl or pirrolidinyl ring.
• the compound according to formula la used is selected from among a group consisting of:
• the compound according to formula I and la used is a compound of general formula (Ib) in which m is 1 or 2;
• R 8 is selected from hydrogen, fluoride, chloride, bromide and methyl;
• R 9 and R 10 are independently selected from hydrogen, lower C( 1-4 )-Alkyl or together with the Nitrogen form an azaheterocyclic ring;
• R 11 is selected from the group consisting of hydrogen, fluoride, chloride, bromide, methyl, trifluoromethyl and methoxy; in the form shown or in form of the acid or base or in form of a salt, especially a physiologically acceptable salt, or in form of a solvate, especially a hydrate.
• the compound according to formula Ib used is characterized in that R 11 is hydrogen.
• the compound according to formula Ib used is characterized in that R 8 is Methyl.
• the compound according to formula Ib used is characterized in that R 9 and R 10 are either hydrogen, CH 3 or C 2 H 5 or together with the Nitrogen form a piperidinyl, morpholinyl or pirrolidinyl ring; preferably in which R 9 and R 10 are either hydrogen, CH 3 or C 2 H 5 ; especially in which R 9 and R 10 are equal and either CH 3 or C 2 H 5 ; most preferably in which R 9 and R 10 are both CH 3 .
• the compound according to formula Ib used is characterized in that m is 1.
• the compound according to formula Ib used is selected from among a group consisting of:
• the compound according to formula la used is a compound of general formula (Ic) in which p is 1 or 2; R 12 is selected from hydrogen, fluoride, chloride, bromide and methyl; R 13 and R 14 are independently selected from hydrogen, lower C (1-4) -Alkyl or together with the Nitrogen form an azaheterocyclic ring; R 15 is selected from the group consisting of hydrogen, fluoride, chloride, bromide, methyl, trifluoromethyl and methoxy.
• the compound according to formula Ic used is characterized in that R 15 is hydrogen.
• the compound according to formula Ic used is characterized in that R 12 is Methyl.
• the compound according to formula Ic used is characterized in that R 13 and R 14 are either hydrogen, CH 3 or C 2 H 5 or together with the Nitrogen form a piperidinyl, morpholinyl or pirrolidinyl ring; preferably in which R 13 and R 14 are either CH 3 or C 2 H 5 ; especially in which R 13 and R 14 are equal and either CH 3 or C 2 H 5 ; most preferably in which R 13 and R 14 are both CH 3 .
• the compound according to formula Ic used is characterized in that p is 1.
• the compound according to formula Ic used is selected from among a group consisting of:
• the compound of the invention are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
• compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon or 15 N-enriched nitrogen are within the scope of this invention.
• a preferred use according to the invention is characterized in that the active compound is used in the medicament at a dose between 50 and 400 mg/day or between 200 and 600 mg/day.
• the complete salt - dose means the dose of the active compound without the salt (which means without the counter ion, for example the citrate ion).
• an effective administered amount of a compound used according to the invention will depend on the relative efficacy of the compound chosen, the severity of the disorder being treated and the weight of the sufferer.
• active compounds will typically be administered once or more times a day for example 1, 2, 3 or 4 times daily, with typical total daily doses in the range of from 0.1 to 1000/mg/kg/day.
• Any formulation or pharmaceutical composition according to the invention contains the active ingredient as well as optionally at least one auxiliary material and/or additive.
• the auxiliary material and/or additive can be selected from carrier, excipient, support materials, glidants, fillers, solvents, diluents, colorants, taste conditioners like sugars, antioxidants and/or binders. In the case of a suppository this might involve waxes or fatty acid esters or conserving agents, emulsifiers and/or carriers for parenteral application.
• carrier excipient
• support materials glidants
• fillers solvents, diluents, colorants
• taste conditioners like sugars, antioxidants and/or binders.
• a suppository this might involve waxes or fatty acid esters or conserving agents, emulsifiers and/or carriers for parenteral application.
• the selection of these auxiliary materials and/or additives and of the amounts to be used depends upon how the pharmaceutical composition is to be applied.
• compositions according to the invention can be adapted for topical or systemical application, especially dermal, subcutaneous, intramuscular, intra-articular and/or intraperitoneal, pulmonal, buccal, sublingual, nasal, percutaneous, vaginal, oral or parenteral, pulmonal, nasal, rectal and/or intravenous application.
• Solid oral compositions (which are preferred as are liquid ones) may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art.
• the tablets may for example be prepared by wet or dry granulation and optionally coated according to the methods well known in normal pharmaceutical practice., in particular with an enteric coating.
• a preferred use according to the invention is characterized in that the medicament is for oral administration, especially in form of a tablet or capsule.
• Another use according to the invention is characterized in that the medicament is in form of an immediate release formulation.
• immediate release formulation means any formulation with a release profile from which measured according to a standard measurement (e.g. using the paddle method according to the Pharmacopeia) (e.g. in 0.1 % NaCl solution) within 30 minutes more than 50 %, more preferably 60 %, or even more preferably 70 % of the active compound is released.
• the use is characterized in that the medicament manufactured is for drug addiction treatment from addiction to opioids.
• the use is characterized in that the medicament manufactured is for for de-addiction treatment from addiction to opioids,
• the use is characterized in that the medicament manufactured is for the amelioration of the effects of a de-addiction treatment from opioids.
• the opioid is opium (which is the dried milky juice of the opium poppy containing opioids (alkaloids)), morphine or heroine or any of its analogues and salts.
• Included in this invention are especially also methods of treatments of a patient or a mammal, including men, suffering from opioid addiction using the compounds described as being used according to this invention.
• Opioid dependency is delevoped in the mice by intraperitoneal administration of the opioid in a suitable dose known to those skilled in the art, e.g. 5 mg/kg/day for 4 consecutive days for morphine. Withdrawal symptoms are then induced by the intravenous administration of a suitable opioid antagonist in a dose known to those skilled in the art, for example, 2 mg/kg naloxone in case of morphine, 30 minutes after the administration of the final dose of the opioid is completed.
• mice show typical withdrawal symptoms, namely jumps and shakes (of the wet dog shake type), which are counted and registered.
• the active substance is administered in combination with the opioid to the mice for 4 consecutive days. After the administration of 2 mg/kg naloxone 30 minutes after the administration of the final dose of the active substance in combination with the opioid has been completed, the mice are closely watched for withdrawal symptoms, namely jumps and shakes (of the wet dog shake type), which are then counted and registered.
• Table A Preparation administered Dosis (mg/kg/day) over 4 days mode of administration Number of Jumps Number of shakes vehicle 1 --- i.p. 0 0 Morphine 5 s.c. 6.6 16.3 Cizorlitine 2 + Morphine 40 + 5 i.p. s.c. 3.1 3.4 1: 5 % by weight arabic gum in water for injection purposes 2: as Citrate salt i.p.: intraperitoneal s.c. subcutaneous

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Addiction (AREA)
• Engineering & Computer Science (AREA)
• Psychiatry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (8)

Applications Claiming Priority (1)

Publications (1)

Family

ID=34926444

Family Applications (2)

Family Applications After (1)

Country Status (7)

Families Citing this family (8)

Citations (5)

Family Cites Families (1)

• 2004
  • 2004-09-07 EP EP04021204A patent/EP1632227A1/fr not_active Withdrawn
• 2005
  • 2005-09-07 WO PCT/EP2005/009594 patent/WO2006027221A1/fr not_active Ceased
  • 2005-09-07 JP JP2007530641A patent/JP2008512414A/ja not_active Withdrawn
  • 2005-09-07 EP EP05784783A patent/EP1786419A1/fr not_active Withdrawn
  • 2005-09-07 CN CNA2005800344766A patent/CN101056631A/zh active Pending
  • 2005-09-07 MX MX2007002773A patent/MX2007002773A/es unknown
  • 2005-09-07 US US11/574,721 patent/US20080200693A1/en not_active Abandoned
  • 2005-09-07 CA CA002578395A patent/CA2578395A1/fr not_active Abandoned

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events